United States · Bill · HR
H.R. 6377 (117th)
Free At-Home Tests for All Act
Introduced
12 January 2022
Last action
13 January 2022 · Referred
Status
Referred to the Subcommittee on Health.
Sponsors
Rep. Beyer, Donald S. [D-VA-8], Rep. Titus, Dina [D-NV-1], Rep. Morelle, Joseph D. [D-NY-25], Kaiali'i Kahele, Rep. Ruiz, Raul [D-CA-25], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Moore, Gwen [D-WI-4], Rep. Bishop, Sanford D. [D-GA-2], Rep. Peters, Scott H. [D-CA-50], Rep. Dean, Madeleine [D-PA-4], Rep. Blumenauer, Earl [D-OR-3], Rep. DeSaulnier, Mark [D-CA-10]
Subjects
Healthcare, Defence
Source updated
3 January 2025
Summary
Free At-Home Tests for All Act This bill requires the Department of Health and Human Services (HHS) to provide free antigen diagnostic tests for COVID-19 (i.e., rapid tests) to U.S. residents. The bill also automatically grants emergency use authorization for rapid tests approved by certain foreign regulators. Specifically, HHS must purchase a sufficient quantity of rapid tests to provide two tests per week at no cost to each resident for the 12 months following the bill's enactment. The President may use authorities available under the Defense Production Act of 1950 to obtain the tests. That act confers upon the President a broad set of authorities to influence domestic industry in order to provide essential materials and goods needed for the national defense. In addition, HHS must conduct outreach about the availability of free rapid tests to Medicare and Medicaid participants and make the tests available through those programs. The bill also automatically grants emergency use authorization during the public health emergency for rapid tests that are listed for emergency use by (1) the World Health Organization (WHO), or (2) a foreign regulator that is a stringent regulatory authority as defined by the WHO for purposes of medicine procurement. The Food and Drug Administration (FDA) may rescind authority for, or otherwise regulate, a rapid test that was automatically authorized. Additionally, the FDA must establish a permanent advisory committee focused on diagnostic and serological testing for public health needs.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
12 January 2022
Introduced
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Financial Services, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Source: IntroReferral
12 January 2022
Introduced
Introduced in House
Source: IntroReferral
12 January 2022
Introduced
Introduced in House
Source: IntroReferral
12 January 2022
Referred
Referred to the Subcommittee on Health.
Source: Committee
13 January 2022
Referred
Referred to the Subcommittee on Health.
Source: Committee
Votes
No vote records are attached yet.
Versions
- Introduced in House · 12 January 2022 · Download file
Documents
3 official files
Introduced in House (text)
This file cannot be previewed here. Use View or Download.
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Introduced in House (text)
Introduced in House · EN · 12 January 2022
Introduced in House (PDF)
Introduced in House · EN · 12 January 2022
ViewDownloadOpen at official source
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Introduced in House
summary · EN · 12 January 2022
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Sponsors
- Rep. Beyer, Donald S. [D-VA-8] · D · Sponsor
- Rep. Titus, Dina [D-NV-1] · D · Sponsor
- Rep. Morelle, Joseph D. [D-NY-25] · D · Sponsor
- Kaiali'i Kahele · D · Sponsor
- Rep. Ruiz, Raul [D-CA-25] · D · Cosponsor
- Del. Norton, Eleanor Holmes [D-DC-At Large] · D · Cosponsor
- Rep. Moore, Gwen [D-WI-4] · D · Cosponsor
- Rep. Bishop, Sanford D. [D-GA-2] · D · Cosponsor
- Rep. Peters, Scott H. [D-CA-50] · D · Cosponsor
- Rep. Dean, Madeleine [D-PA-4] · D · Cosponsor
- Rep. Blumenauer, Earl [D-OR-3] · D · Cosponsor
- Rep. DeSaulnier, Mark [D-CA-10] · D · Cosponsor
- · hsif00 · Standing
- · hswm00 · Standing
- · hsba00 · Standing
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/117th-congress/house-bill/6377
- Open data entity: https://api.congress.gov/v3/bill/117/hr/6377
- us · 117-hr-6377 · source updated 3 January 2025